Report cover image

CAR-T Cell Therapy Market Review

Publisher Kalorama Information
Published Dec 19, 2019
Length 59 Pages
SKU # KLI16126453

Description

CAR-T Cell Therapy Market Review

CAR-T cell therapy is a form of immunotherapy that utilizes the body’s own T cells to target and destroy cancer cells. This therapy is a personalized form of treatment, meaning that each patient receives T cells that are geared specifically toward his or her cancer diagnosis. T-cell therapy works by removing existing T cells from a patient and having them grown and modified in a lab. These new T cells are given a gene for a specialized receptor, known as a chimeric antigen receptor (CAR), which allows the cells to specifically attack cancer cells. CAR-T cell therapy has shown effectiveness in eliminating cancer cells, especially for the following diseases:
  • Acute lymphoblastic leukemia (ALL)
  • DLBCL B-cell lymphomas
  • Multiple myeloma
CAR-T Cell Therapy Market Review discusses CAR-T’s impressive revenue growth, which is expected to continue given the effectiveness of the therapy and the projected new users. There are positive factors for the market, though there are limits to growth. Patient volume should increase, though it is likely that the unusually large prices will not sustain over the next five years. The report provides the following market data:
  • CAR-T Market, 2018-2024 ($millions)
  • CAR-T Market Share, 2019 (%)
  • CAR-T Market Regional Breakout, 2019 (%)
CAR-T Cell Therapy Market Review discusses CAR-T therapy market trends, issues, and recent developments, including the following:
  • Global Cancer Burden
  • Complexity of the CARs Manufacturing Process
  • Diseases Treated with CAR-T
  • Study Shows Yescarta Increases Longevity
  • CRS and Other Side Effects
  • China CAR-T Competition
  • Indian CAR-T Competition
  • "Off-the-Shelf" CAR-T Therapies in Development
  • Competing Therapy in Development
Also noted in the report are selected CAR-T therapies in development, an effort to capture current media coverage of CAR-T trials. CAR-T Cell Therapy Market Review notes the activities of many of the major players in the market. The market companies that are covered in the report are the following:
  • AbbVie, Inc.
  • Autolus Therapeutics plc
  • Bellicum Pharmaceuticals, Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics
  • Celgene Corporation
  • Cellectis, Inc.
  • Celyad
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Immune Therapeutics
  • Innovative Cellular Therapeutics
  • Juno Therapeutics
  • Kite Pharma, Inc.
  • Mustang Bio
  • Novartis International AG
  • Pfizer, Inc.
  • Sorrento Therapeutics
  • ZIOPHARM Oncology, Inc.

Table of Contents

59 Pages
    • Introduction
    • CAR-T Therapy Market Trends, Issues, and Recent Developments
    • CAR-T Therapy Market
    • Companies in the Market
    • FDA-Approved CAR-T Therapies: Yescarta and Kymriah
    • CAR-T Therapy Market Trends / Issues
    • Recent Market Developments
    • Selected CAR-T Therapies in Development
    • CAR-T Market Analysis
    • AbbVie, Inc.
    • Autolus Therapeutics plc
    • Bellicum Pharmaceuticals, Inc.
    • bluebird bio, Inc.
    • Bristol-Myers Squibb Company
    • CARsgen Therapeutics
    • Celgene Corporation
    • Cellectis, Inc.
    • Celyad
    • Gilead Sciences, Inc.
    • GlaxoSmithKline
    • Gracell Biotechnology
    • Immune Therapeutics
    • Innovative Cellular Therapeutics
    • Juno Therapeutics
    • Kite Pharma, Inc.
    • Mustang Bio
    • Novartis International AG
    • Pfizer, Inc.
    • Sorrento Therapeutics
    • ZIOPHARM Oncology, Inc.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us